|
1
|
Dohner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khwaja A, Bjorkholm M, Gale RE, Levine RL,
Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A,
Cornelissen JJ, et al: Acute myeloid leukaemia. Nat Rev Dis
Primers. 2:160102016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sasine JP and Schiller GJ: Emerging
strategies for high-risk and relapsed/refractory acute myeloid
leukemia: Novel agents and approaches currently in clinical trials.
Blood Rev. 29:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shafer D and Grant S: Update on rational
targeted therapy in AML. Blood Rev. 30:275–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nair R, Salinas-Illarena A and Baldauf HM:
New strategies to treat AML: Novel insights into AML survival
pathways and combination therapies. Leukemia. 35:299–311. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Short NJ, Konopleva M, Kadia TM, Borthakur
G, Ravandi F, DiNardo CD and Daver N: Advances in the treatment of
acute myeloid leukemia: New drugs and new challenges. Cancer
Discov. 10:506–525. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dohner H, Estey EH, Amadori S, Appelbaum
FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karathedath S, Rajamani BM, Musheer Aalam
SM, Abraham A, Varatharajan S, Krishnamurthy P, Mathews V,
Velayudhan SR and Balasubramanian P: Role of NF-E2 related factor 2
(Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML)
and the effect of pharmacological inhibition of Nrf2. PLoS One.
12:e01772272017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shafat MS, Gnaneswaran B, Bowles KM and
Rushworth SA: The bone marrow microenvironment-Home of the leukemic
blasts. Blood Rev. 31:277–286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tong F, Zhang J, Liu L, Gao X, Cai Q, Wei
C, Dong J, Hu Y, Wu G and Dong X: Corilagin attenuates
radiation-induced brain injury in mice. Mol Neurobiol.
53:6982–6996. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Deng Y, Zheng Z, Huang W, Chen L,
Tong Q and Ming Y: Corilagin, a promising medicinal herbal agent.
Biomed Pharmacother. 99:43–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu J, Ye C, Huang Y, Huang D, Tang L, Hou
W, Kuang Z, Chen Y, Xiao S, Yishake M and He R: Corilagin
suppresses RANKL-induced osteoclastogenesis and inhibits oestrogen
deficiency-induced bone loss via the NF-κB and PI3K/AKT signalling
pathways. J Cell Mol Med. 24:10444–10457. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gambari R, Borgatti M, Lampronti I, Fabbri
E, Brognara E, Bianchi N, Piccagli L, Yuen MC, Kan CW, Hau DK, et
al: Corilagin is a potent inhibitor of NF-kappaB activity and
downregulates TNF-alpha induced expression of IL-8 gene in cystic
fibrosis IB3-1 cells. Int Immunopharmacol. 13:308–315. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao HT, Lin CY, Ho DH, Peng J, Chen Y,
Tsang SW, Wong M, Zhang XJ, Zhang M and Bian ZX: Inhibitory effect
of the gallotannin corilagin on dextran sulfate sodium-induced
murine ulcerative colitis. J Nat Prod. 76:2120–2125. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Milani R, Brognara E, Fabbri E, Finotti A,
Borgatti M, Lampronti I, Marzaro G, Chilin A, Lee KK, Kok SH, et
al: Corilagin induces high levels of apoptosis in the
temozolomide-resistant T98G glioma cell line. Oncol Res.
26:1307–1315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tong Y, Zhang G, Li Y, Xu J, Yuan J, Zhang
B, Hu T and Song G: Corilagin inhibits breast cancer growth via
reactive oxygen species-dependent apoptosis and autophagy. J Cell
Mol Med. 22:3795–3807. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y
and Yu Y: A potential anti-tumor herbal medicine, Corilagin,
inhibits ovarian cancer cell growth through blocking the TGF-β
signaling pathways. BMC Complement Altern Med. 13:332013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Emmrich S, Katsman-Kuipers JE, Henke K,
Khatib ME, Jammal R, Engeland F, Dasci F, Zwaan CM, den Boer ML,
Verboon L, et al: MiR-9 is a tumor suppressor in pediatric AML with
t(8;21). Leukemia. 28:1022–1032. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
So AY, Sookram R, Chaudhuri AA,
Minisandram A, Cheng D, Xie C, Lim EL, Flores YG, Jiang S, Kim JT,
et al: Dual mechanisms by which miR-125b represses IRF4 to induce
myeloid and B-cell leukemias. Blood. 124:1502–1512. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y, Cheng Z, Pang Y, Cui L, Qian T,
Quan L, Zhao H, Shi J, Ke X and Fu L: Role of microRNAs, circRNAs
and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol.
12:512019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang X, Hu C, Arnovitz S, Bugno J, Yu M,
Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, et al: MiR-22 has a
potent anti-tumour role with therapeutic potential in acute myeloid
leukaemia. Nat Commun. 7:114522016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wallace JA and O'Connell RM: MicroRNAs and
acute myeloid leukemia: Therapeutic implications and emerging
concepts. Blood. 130:1290–1301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu L, Ren W and Chen K: MiR-34a promotes
apoptosis and inhibits autophagy by targeting HMGB1 in acute
myeloid leukemia cells. Cell Physiol Biochem. 41:1981–1992. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Liu Y and Xu X: Upregulation of
miR-142-3p improves drug sensitivity of acute myelogenous leukemia
through reducing P-glycoprotein and repressing autophagy by
targeting HMGB1. Transl Oncol. 10:410–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su R, Gong JN, Chen MT, Song L, Shen C,
Zhang XH, Yin XL, Ning HM, Liu B, Wang F, et al: c-Myc suppresses
miR-451 dash, verticalYWTAZ/AKT axis via recruiting HDAC3 in acute
myeloid leukemia. Oncotarget. 7:77430–77443. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song L, Lin HS, Gong JN, Han H, Wang XS,
Su R, Chen MT, Shen C, Ma YN, Yu J and Zhang JW:
MicroRNA-451-modulated hnRNP A1 takes a part in granulocytic
differentiation regulation and acute myeloid leukemia. Oncotarget.
8:55453–55466. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao J, Da Y, Li H, Peng Y and Hu X:
Upregulation of microRNA-451 attenuates myocardial I/R injury by
suppressing HMGB1. PLoS One. 15:e02356142020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amato J, Cerofolini L, Brancaccio D,
Giuntini S, Iaccarino N, Zizza P, Iachettini S, Biroccio A,
Novellino E, Rosato A, et al: Insights into telomeric G-quadruplex
DNA recognition by HMGB1 protein. Nucleic Acids Res. 47:9950–9966.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao
L, Huang J, Yu Y, Fan XG, Yan Z, et al: HMGB1 in health and
disease. Mol Aspects Med. 40:1–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang R, Livesey KM, Zeh HJ, Loze MT and
Tang D: HMGB1: A novel Beclin 1-binding protein active in
autophagy. Autophagy. 6:1209–1211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pan B, Chen D, Huang J, Wang R, Feng B,
Song H and Chen L: HMGB1-mediated autophagy promotes docetaxel
resistance in human lung adenocarcinoma. Mol Cancer. 13:1652014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hou X, Yang C, Zhang L, Hu T, Sun D, Cao
H, Yang F, Guo G, Gong C, Zhang X, et al: Killing colon cancer
cells through PCD pathways by a novel hyaluronic acid-modified
shell-core nanoparticle loaded with RIP3 in combination with
chloroquine. Biomaterials. 124:195–210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu L, Zhang J, Zhang X, Cheng P, Liu L,
Huang Q, Liu H, Ren S, Wei P, Wang C, et al: HMGB1: An important
regulator of myeloid differentiation and acute myeloid leukemia as
well as a promising therapeutic target. J Mol Med (Berl).
99:107–118. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang R, Xu Y, Wan W, Shou X, Qian J, You
Z, Liu B, Chang C, Zhou T, Lippincott-Schwartz J and Liu W:
Deacetylation of nuclear LC3 drives autophagy initiation under
starvation. Mol Cell. 57:456–466. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang F, Wang Y, Xue J, Ma Q, Zhang J, Chen
YF, Shang ZZ, Li QQ, Zhang SL and Zhao L: Effect of corilagin on
the miR-21/smad7/ERK signaling pathway in a schistosomiasis-induced
hepatic fibrosis mouse model. Parasitol Int. 65:308–315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou X, Xiong J, Lu S, Luo L, Chen ZL,
Yang F, Jin F, Wang Y, Ma Q, Luo YY, et al: Inhibitory effect of
corilagin on miR-21-regulated hepatic fibrosis signaling pathway.
Am J Chin Med. 47:1541–1569. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Chu X and Wei Q: MiR-451 promotes
cell apoptosis and inhibits autophagy in pediatric acute myeloid
leukemia by targeting HMGB1. J Environ Pathol Toxicol Oncol.
40:45–53. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pistritto G, Trisciuoglio D, Ceci C,
Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: Function
and dysfunction of its modulators and targeted therapeutic
strategies. Aging (Albany NY). 8:603–619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rai KR, Moore J, Wu J, Novick SC and
O'Brien SM: Effect of the addition of oblimersen (Bcl-2 antisense)
to fludarabine/cyclophosphamide for replased/refractory chronic
lymphocytic leukaemia (CLL) on survival in patients who achieve
CR/nPR: Five-year follow-up from a randomized phase III study. J
Clin Oncol. 26 (Suppl 15):S70082008. View Article : Google Scholar
|
|
41
|
Shangary S and Wang S: Small-molecule
inhibitors of the MDM2-p53 protein-protein interaction to
reactivate p53 function: A novel approach for cancer therapy. Annu
Rev Pharmacol Toxicol. 49:223–241. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hu H, Tian M, Ding C and Yu S: The C/EBP
homologous protein (CHOP) transcription factor functions in
endoplasmic reticulum stress-induced apoptosis and microbial
infection. Front Immunol. 9:30832018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dikic I and Elazar Z: Mechanism and
medical implications of mammalian autophagy. Nat Rev Mol Cell Biol.
19:349–364. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Maiuri MC, Zalckvar E, Kimchi A and
Kroemer G: Self-eating and self-killing: Crosstalk between
autophagy and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Q, Yin Y, Zheng Y, Chen F and Jin P:
Inhibition of autophagy promoted high glucose/ROS-mediated
apoptosis in ADSCs. Stem Cell Res Ther. 9:2892018. View Article : Google Scholar : PubMed/NCBI
|
